FDA granted Breakthrough Therapy Designation for Genmab's Rina-S, while the company also faces potential challenges from Trump's tariffs.
4 reports, 3 independent
Updated Sep 6
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA granted Breakthrough Therapy Designation for Genmab's Rina-S, while the company also faces potential challenges from Trump's tariffs.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Genmab received FDA designation for Rina-S, but the company must contend with potential tariffs from Trump.1 source
Genmab presented results at the SOHO meeting.1 source
Keep exploring
The entities involved
- FDA
-
Genmab
Danish healthcare company
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
Related events
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- Ro Khanna compared his AI regulatory proposal to the FDA model.
- The FDA is facing public scrutiny due to oversight failures, leading to the introduction of new legislation targeting agency shortcomings.
- FDA is reviewing a new sunscreen ingredient while NPR reports on Donald Trump's political tensions.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Coverage
Newest first; wire copies grouped- Simply Wall St.Genmab (CPSE:GMAB) Is Up 10.3% After FDA Breakthrough for Rina-S in Endometrial Cancer – Has The Bull Case Changed? Genmab A/S recently announced that its investigational antibody-drug conjugate, rin
- Business WireGenmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma
- Business WireGenmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC) Breakthrough Therapy Designation granted to Rina-S for the treatment of adu
- GlobeNewswireGenmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC) Media Release COPENHAGEN, Denmark; August 26, 2025 Breakthrough Therapy Des